Your browser doesn't support javascript.
loading
New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 633-637, 2021.
Article in Chinese | WPRIM | ID: wpr-880125
ABSTRACT
Primary central nervous system lymphoma (PCNSL) is a rare aggressive non-Hodgkin's lymphoma outside the lymph nodes. At present, high-dose chemotherapy based on methotrexate is the standard induction therapy for newly diagnosed PCNSL, but the effective therapy of relapse/refractory and elderly PCNSL is still unclear. With the progress of clinical trials, new drugs and combined treatment method appear constantly, such as rituximab and ibrutinib, the remission rate of refractory and relapsed patients increased, while lenalidomide showed a good activity in the maintenance treatment of elderly patients. This review summarized briefly the recent advances of research on immunocheckpoint inhibitors, immunoregulatory agents, bruton tyrosine kinase (BTK) and PI3K/AKT/mTOR pathway inhibitors.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Lymphoma, Non-Hodgkin / Antineoplastic Combined Chemotherapy Protocols / Central Nervous System / Central Nervous System Neoplasms / Phosphatidylinositol 3-Kinases / Neoplasm Recurrence, Local Limits: Aged / Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Lymphoma, Non-Hodgkin / Antineoplastic Combined Chemotherapy Protocols / Central Nervous System / Central Nervous System Neoplasms / Phosphatidylinositol 3-Kinases / Neoplasm Recurrence, Local Limits: Aged / Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article